Novartis Opens Production Facility for Innovative Eye Retina Product in Tyrol

Companies › Health Care ♦ Published: June 20, 2020; 10:30 ♦ (Vindobona)

The pharmaceutical company Novartis is investing EUR 27.4 million in the Kundl site in Tyrol to produce an active ingredient for a new therapy for wet age-related macular degeneration with 40 employees.

Novartis plant in Kundl, Kufstein, Tyrol, Austria. / Picture: © Novartis

The pharmaceutical company Novartis has announced the start of global production of an innovative retinal drug at its Kundl site in Tyrol.

"This compound is a humanized single-chain antibody fragment that requires cutting-edge expertise to produce. …

or Log In

Fast News Search
Related News
COVID-19 Drug Made in Austria (May 19)
Austria Becomes Self-sufficient in the Supply of Mouth and Nose Masks (May 19)
Pfizer Invests 50 Million Euros in Lower Austria (August 28, 2019)
Swiss Pharmaceutical Group Invests 142 Million Euros in its Viennese Research Facilities (October 25, 2018)
Read More
Novartis, Health Industry, Switzerland, Mario Riesner, Michael Kocher, Tyrol, FDI Foreign Direct Investments
Featured
Update: Lockdown in Austria - What applies from Monday 7 December?
Austria Launches CoV Mass Testing: Vienna Tests at 3 Locations until December 13 - How does it work?
List of National Days of the Home Countries of All Foreign Missions and Delegations in Vienna, Austria
See latest Vindobona Newsletter